Buscar

Health is a fundamental human right, and achieving equality in access to medicines is crucial for ensuring public health. The current system of innovation strongly relies on the private sector, while remuneration of innovation is mainly based on exclusivities. This system presents several issues, such as innovation being driven by market size, the partial misalignment between industry’s research and development (R&D) priorities and public health goals, access constraints, and the scarcity of disruptive ...

Este estudio presenta una cartografía de los fondos aportados por distintos actores para la I+D y la expansión de la capacidad de producción de vacunas contra la COVID-19, centrándose en aquellas autorizadas en la Unión. Se examinan nueve vacunas. Se observa que los Gobiernos, principalmente el de Estados Unidos (con algunas entidades sin ánimo de lucro), apoyaron decididamente inversiones empresariales, tanto en I+D como en fabricación o en ambas cosas, por valor de casi 9000 millones de euros, ...

Antimicrobial resistance (AMR) is a global, multidimensional phenomenon occurring in humans, animals, and environmental ecosystems. It is the ability of microbes, e.g. bacteria, viruses, fungi and protozoa, to survive in the presence of medicines designed to kill or inactivate them (antimicrobials: antibiotics, antivirals, antifungals and antiprotozoals). At patient level, AMR hampers the effective treatment of microbial infections, leading to prolonged, severe disease and, in some cases, death. ...

Cancer can affect everyone, regardless of age, gender or social status and puts immense pressure on European health systems. Fighting cancer is one of the priorities of the European Health Union. Delivering better long-term care for patients living with cancer also means reducing significant disparities, both between and within Member States. World Cancer Day, marked every year on 4 February, reminds us that cancer is a huge health threat to our society.

The European Commission plans to launch its revised EU pharmaceutical package in the first quarter of 2023. Ahead of its release, two recent STOA studies offer insight to inform upcoming Parliamentary discussions. Fragmentation of EU health research and development, lack of transparency and a translation gap between public investment and clinical output are among the weaknesses identified. Possible solutions include the creation of large-scale European biomedical infrastructure, and a series of targeted ...

World AIDS Day, proclaimed by the United Nations in 1988, takes place each year on 1 December. The aim is to raise awareness, fight prejudice, encourage progress in prevention, and improve treatment around the world. Although infection with the human immunodeficiency virus (HIV) is preventable, significant HIV transmission remains a challenge to EU Member States' health systems. This year's theme 'Equalize' underlines the urgent need to address the inequalities that are holding back progress in ending ...

These proceedings summarise the presentations and discussions before the European Parliament’s Health Working Group as part of the workshop on ‘New incentives to improve the accessibility and availability of antimicrobial medicinal products’, held on 26 October 2022. The five presentations touched, inter alia, upon the burden of AMR, the current research on development of antimicrobials, and incentive models. These workshop proceedings were provided by the Policy Department for Economic, Scientific ...

Antimicrobial-resistant infections are predicted to become the second biggest cause of death worldwide by 2050. Despite increasing investment in the development of new antimicrobials, awareness campaigns on antimicrobial misuse and abuse, and monitoring of antimicrobial use and resistance in animals, humans and the environment, antimicrobial resistance continues to grow and the last three decades have not seen even one novel antimicrobial class reach the market. Could the answer lie in a 'Trojan ...

Durante el período parcial de sesiones de febrero, se espera que el Parlamento debata el informe final de su Comisión Especial sobre Lucha contra el Cáncer y en las que se piden medidas políticas específicas en este ámbito crucial de la salud pública.

As part of building a European Health Union, as well as in response to the Covid 19 pandemic, the European Commission proposed in November 2020 to reinforce the European Medicines Agency's role in crisis preparedness and the management of medicines and medical devices. The proposed regulation seeks to better anticipate possible shortages and to ensure timely development of high-quality medicinal solutions, to allow the EU to react to health crises more quickly, efficiently, and in a coordinated manner ...